You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 2, February 1983 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE SECOND ANNUAL MEETING OF THE SURGICAL INFECTION SOCIETY, BOSTON, APRIL 19-20, 1982-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Mechanisms of In Vitro Sensitivity to Sulfadiazine Silver

Albert T. McManus, PhD; Camille L. Denton, MA; Arthur D. Mason, Jr, MD

Arch Surg. 1983;118(2):161-166.


Abstract

• Sulfonamide-resistant organisms have been reported as a frequent consequence of the clinical use of sulfadiazine silver. At this burn center, sulfonamide resistance occurred in more than 80% of gram-negative isolates. We tested the requirement for the individual antimicrobial activities of sulfadiazine and silver for in vitro activity of sulfadiazine silver. The sulfadiazine component is not necessary for in vitro sensitivity. In vitro sensitivity to sulfadiazine silver does not consistently predict the presence of therapeutic activity in Pseudomonas aeruginosa–infected rats with burns. We describe an example of a transferable multiple-antibiotic resistance plasmid that contains selectable sulfonamide resistance. The use of sulfadiazine silver can, therefore, lead to the selection of organisms that are resistant not only to sulfonamides but to antibiotics of clinical consequence, and this possible risk must be considered in electing to use the agent.

(Arch Surg 1983;118:161-166)



Author Affiliations

From the US Army Institute of Surgical Research, Fort Sam Houston, Tex.


Footnotes

Accepted for publication Oct 5, 1982.

Read before the second annual meeting of the Surgical Infection Society, Boston, April 19, 1982.

The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.

Reprint requests to Library, US Army Institute of Surgical Research, Fort Sam Houston, TX 78234 (Dr McManus).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Burn Wound Sepsis
Hansbrough
J Intensive Care Med 1987;2:313-327.
ABSTRACT  

Microbial Colonization in a New Intensive Care Burn Unit: A Prospective Cohort Study
McManus et al.
Arch Surg 1985;120:217-223.
ABSTRACT  

Topical Chlorhexidine Diphosphanilate (WP-973) in Burn Wound Sepsis
McManus et al.
Arch Surg 1984;119:206-211.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.